MedTrace Logo

An Expanded Access Program of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant

NCT03147742 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2022-06-07

No results posted yet for this study

Summary

To provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD.

Conditions

  • Graft-versus-host Disease (GVHD)

Interventions

DRUG

Ruxolitinib

Ruxolitinib starting dose level 10 mg orally, twice daily (BID).

Sponsors & Collaborators

Principal Investigators

  • John Galvin, MD · Incyte Corporation

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03147742 on ClinicalTrials.gov